Scholarlink

Background <p>Tumour associated autoantibody (TAAb) generated against cell membrane receptor proteins in lung cancer have attracted attention. Understanding the role of these autoantibodies in tumours may open up new therapeutic modalities.</p> Methods <p>Plasma samples from 1170 participants were used to detect TAAbs level by enzyme-linked immunosorbent assay (ELISA) for evaluating the diagnostic value of candidate TAAbs. 353 non-small cell lung cancer (NSCLC) cases were used to assess the prognostic value of anti-platelet-derived growth factor receptor alpha (PDGFRα) autoantibody. The impact and mechanisms of anti-PDGFRα autoantibody were explored through antibody absorption, CCK-8, transwell, wound healing, and angiogenesis assays in NCI-H1703 cell.</p> Results <p>Anti - PDGFRα autoantibody was overexpressed in NSCLC and had an AUC of 0.747 (95% CI: 0.701-0.794) for early diagnosis compared to normal individuals. Cox regression analysis showed that it could be served as an independent predictor of poor prognosis in NSCLC with a HR of 1.510 (95% CI: 1.094-2.098). In vitro results suggested a role of anti-PDGFRα in promoting proliferation, migration, and angiogenesis via PI3K/AKT/NF-κB pathway.</p> Conclusions <p>Anti-PDGFRα autoantibody is a novel biomarker for early diagnosis and poor prognosis of NSCLC. The mechanisms exploration may provide the theoretical basis for the precision treatment of NSCLC targeting anti-PDGFRα autoantibody.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anti-PDGFRα autoantibody – a novel diagnostic and prognostic marker – may mediate non-small cell lung cancer progression via the PI3K/AKT/NF-κB signaling pathway

  • 期刊论文

  • 发表日期：

    2026年6月27日

查看全文
  • Fengqi Chen,
  • Ying Chen,
  • Wenke Sun,
  • Hanke Ma,
  • Yihao Liang,
  • Yutong Li,
  • Jing Li,
  • Xiaobin Cao,
  • Songyun Ouyang,
  • Liping Dai

摘要

Background

Tumour associated autoantibody (TAAb) generated against cell membrane receptor proteins in lung cancer have attracted attention. Understanding the role of these autoantibodies in tumours may open up new therapeutic modalities.

Methods

Plasma samples from 1170 participants were used to detect TAAbs level by enzyme-linked immunosorbent assay (ELISA) for evaluating the diagnostic value of candidate TAAbs. 353 non-small cell lung cancer (NSCLC) cases were used to assess the prognostic value of anti-platelet-derived growth factor receptor alpha (PDGFRα) autoantibody. The impact and mechanisms of anti-PDGFRα autoantibody were explored through antibody absorption, CCK-8, transwell, wound healing, and angiogenesis assays in NCI-H1703 cell.

Results

Anti - PDGFRα autoantibody was overexpressed in NSCLC and had an AUC of 0.747 (95% CI: 0.701-0.794) for early diagnosis compared to normal individuals. Cox regression analysis showed that it could be served as an independent predictor of poor prognosis in NSCLC with a HR of 1.510 (95% CI: 1.094-2.098). In vitro results suggested a role of anti-PDGFRα in promoting proliferation, migration, and angiogenesis via PI3K/AKT/NF-κB pathway.

Conclusions

Anti-PDGFRα autoantibody is a novel biomarker for early diagnosis and poor prognosis of NSCLC. The mechanisms exploration may provide the theoretical basis for the precision treatment of NSCLC targeting anti-PDGFRα autoantibody.